🚀 VC round data is live in beta, check it out!
GSK India Valuation Multiples
Discover revenue and EBITDA valuation multiples for GSK India and similar public comparables like Yakult Honsha, Beijing Tiantan, TG Therapeutics, e.l.f. Beauty and more.
GSK India Overview
About GSK India
GlaxoSmithKline Pharmaceuticals Ltd is an India-based subsidiary of GlaxoSmithKline plc. GSK India develops and manufactures medicines, vaccines, and consumer products. Its medicines portfolio includes prescription drugs for conditions that include asthma, infectious diseases, mental health, and digestion, as well as nonprescription nutrition and cosmetic products. Its vaccine product line includes treatments for conditions such as influenza, HPV, hepatitis, and measles. Its consumer healthcare products include Horlicks-brand packaged food and beverage powders among other retail products. The company derives a majority of its revenue from India.
Founded
1924
HQ
Employees
3.1K
Website
Financials (LTM)
EV
$5B
GSK India Financials
GSK India reported last 12-month revenue of $414M and EBITDA of $142M.
In the same LTM period, GSK India generated $264M in gross profit, $142M in EBITDA, and $111M in net income.
Revenue (LTM)
GSK India P&L
In the most recent fiscal year, GSK India reported revenue of $439M and EBITDA of $140M.
GSK India expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $414M | XXX | $439M | XXX | XXX | XXX |
| Gross Profit | $264M | XXX | $238M | XXX | XXX | XXX |
| Gross Margin | 64% | XXX | 54% | XXX | XXX | XXX |
| EBITDA | $142M | XXX | $140M | XXX | XXX | XXX |
| EBITDA Margin | 34% | XXX | 32% | XXX | XXX | XXX |
| EBIT Margin | 34% | XXX | 31% | XXX | XXX | XXX |
| Net Profit | $111M | XXX | $108M | XXX | XXX | XXX |
| Net Margin | 27% | XXX | 25% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
GSK India Stock Performance
GSK India has current market cap of $5B, and enterprise value of $5B.
Market Cap Evolution
GSK India's stock price is $27.99.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $5B | $5B | -0.4% | XXX | XXX | XXX | $0.64 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialGSK India Valuation Multiples
GSK India trades at 10.9x EV/Revenue multiple, and 31.9x EV/EBITDA.
EV / Revenue (LTM)
GSK India Financial Valuation Multiples
As of March 27, 2026, GSK India has market cap of $5B and EV of $5B.
Equity research analysts estimate GSK India's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
GSK India has a P/E ratio of 42.6x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $5B | XXX | $5B | XXX | XXX | XXX |
| EV (current) | $5B | XXX | $5B | XXX | XXX | XXX |
| EV/Revenue | 10.9x | XXX | 10.3x | XXX | XXX | XXX |
| EV/EBITDA | 31.9x | XXX | 32.3x | XXX | XXX | XXX |
| EV/EBIT | 32.3x | XXX | 33.4x | XXX | XXX | XXX |
| EV/Gross Profit | 17.1x | XXX | 19.0x | XXX | XXX | XXX |
| P/E | 42.6x | XXX | 43.8x | XXX | XXX | XXX |
| EV/FCF | 69.6x | XXX | 28.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified GSK India Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
GSK India Margins & Growth Rates
GSK India's revenue in the last 12 month grew by 10%.
GSK India's revenue per employee in the last FY averaged $0.1M.
GSK India's rule of 40 is 44% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
GSK India's rule of X is 59% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
GSK India Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 10% | XXX | (6%) | XXX | XXX | XXX |
| EBITDA Margin | 34% | XXX | 32% | XXX | XXX | XXX |
| EBITDA Growth | 11% | XXX | 1% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 44% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 59% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 5% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 1% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 27% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
GSK India Public Comps
See public comps and valuation multiples for other Biopharmaceuticals and Health & Beauty comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Yakult Honsha | XXX | XXX | XXX | XXX | XXX | XXX |
| Beijing Tiantan | XXX | XXX | XXX | XXX | XXX | XXX |
| TG Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| e.l.f. Beauty | XXX | XXX | XXX | XXX | XXX | XXX |
| Terns Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
GSK India M&A Activity
GSK India acquired XXX companies to date.
Last acquisition by GSK India was on XXXXXXXX, XXXXX. GSK India acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by GSK India
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialGSK India Investment Activity
GSK India invested in XXX companies to date.
GSK India made its latest investment on XXXXXXXX, XXXXX. GSK India invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by GSK India
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout GSK India
| When was GSK India founded? | GSK India was founded in 1924. |
| Where is GSK India headquartered? | GSK India is headquartered in India. |
| How many employees does GSK India have? | As of today, GSK India has over 3K employees. |
| Is GSK India publicly listed? | Yes, GSK India is a public company listed on National Stock Exchange of India. |
| What is the stock symbol of GSK India? | GSK India trades under GLAXO ticker. |
| When did GSK India go public? | GSK India went public in 2000. |
| Who are competitors of GSK India? | GSK India main competitors are Yakult Honsha, Beijing Tiantan, TG Therapeutics, e.l.f. Beauty. |
| What is the current market cap of GSK India? | GSK India's current market cap is $5B. |
| What is the current revenue of GSK India? | GSK India's last 12 months revenue is $414M. |
| What is the current revenue growth of GSK India? | GSK India revenue growth (NTM/LTM) is 10%. |
| What is the current EV/Revenue multiple of GSK India? | Current revenue multiple of GSK India is 10.9x. |
| Is GSK India profitable? | Yes, GSK India is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of GSK India? | GSK India's last 12 months EBITDA is $142M. |
| What is GSK India's EBITDA margin? | GSK India's last 12 months EBITDA margin is 34%. |
| What is the current EV/EBITDA multiple of GSK India? | Current EBITDA multiple of GSK India is 31.9x. |
| What is the current FCF of GSK India? | GSK India's last 12 months FCF is $65M. |
| What is GSK India's FCF margin? | GSK India's last 12 months FCF margin is 16%. |
| What is the current EV/FCF multiple of GSK India? | Current FCF multiple of GSK India is 69.6x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.